Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Decitabine/THU Formulations in Healthy Adults
NCT04086238Phase 1Completed
- Sponsor
- EpiDestiny
- Start
- Oct 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of decitabine and tetrahydrouridine in sickle cell disease (SCD) and beta thalassemia (6 arms), sponsored by EpiDestiny. Primary endpoints: Absorption of Decitabine at 24 hours, Decitabine plasma concentration at 24 hours and 1 more. Started Oct 2019; status: completed.
02
Drugs
decitabinetetrahydrouridine
03
Conditions
sickle cell disease (SCD)beta thalassemia
Beyond the preview
Go deeper on NCT04086238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04086238.